Sellas Life Sciences Group (SLS) has been flagged for having some of the highest borrow fees in the current IBKR securities lending dataset. High borrow costs are a classic indicator of a 'hard-to-borrow' status, often driven by a scarcity of available shares for short sellers to borrow. This environment creates a high-pressure scenario for existing shorts, as the cost of maintaining the position increases significantly over time. Traders should monitor for any sudden spikes in volume or price, as high borrow fees often precede volatility in small-cap biotech names.
Signal data sourced from Interactive Brokers. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.